Home › Gender Dysphoria › NCT04596592
Pubertal Blockade and Estradiol Effects on Cardiometabolic Health for Transitioning Youth
RecruitingObservational study
Who can join
Ages 13 to 16 · All sexes
Full eligibility criteria
Inclusion Criteria (transgender females): * Identify as a transgender female * Age 13-16 years at the time of enrollment * If on a gonadotropin releasing hormone analogue, \> 6 months exposure * Plan to start estradiol clinically in \< 4 months Inclusion Criteria (cisgender males and females): * Males and females ages 13-16 years Exclusion Criteria: * Cognitive, psychiatric, or physical impairment resulting in inability to tolerate the study procedures * Antipsychotic medication use * Type 1 or 2 diabetes (by medical history) * Polycystic ovarian syndrome (PCOS for cisgender females) * Hypertension (resting BP ≥ 140/90 mm/Hg) * Weight\> 400 lbs * On oral progesterone medications (including oral progesterone or progestin, combined oral contraceptives or etonogestrel implant) * Pregnancy (for cisgender females)
About the study
To evaluate the effect of estradiol with or without a prior gonadotropin releasing hormone analogue on insulin sensitivity and vascular function in transgender females compared to cisgender controls.
Sponsor: University of Colorado, Denver · Participants: 90 · Started: Feb 15, 2021
Contact the study team
- Natalie Nokoff, MD, MSCS · Phone: 720-777-3607
Official record on ClinicalTrials.gov — NCT04596592
Locations in the U.S.
| Colorado | Children's Hospital Colorado, Aurora |
Conditions
From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.